-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shionogi and F2G announced a strategic collaboration to develop and commercialize olorofim, a novel antifungal drug for the treatment of invasive fungal infections, in Europe and As.
Invasive aspergillosis (IA) is a potentially fatal rare disease that occurs primarily in immunocompromised patients, including those who have received cancer chemotherapy or hematopoietic stem cell transplantati.
Olorofim (F901318) is a novel oral antifungal drug developed by F2G for the treatment of IA and other rare fungal infectio.
▲Olorofim molecular structure (Image source: PubChem)
Olorofim is currently undergoing a Phase 2b open-label stu.
Under the terms of the agreement, Shionogi will conduct clinical trials and subsequent registration and commercialization of olorofim for the treatment of IA in Europe and As.
References:
Shionogi & .
Note: The original text has been deleted